Candidaemia in a European Paediatric University Hospital: A 10-year observational study

Clinical Microbiology and Infection

Volumn 18, Issue 2, 2012, Pages

  Tragiannidis, A ^a,b   Fegeler, W ^a   Rellensmann, G ^a   Debus, V ^a   Muller V ^a   Hoernig Franz, I ^a   Siam, K ^a   Pana, Z D ^b   Jurgens H ^a   Groll, A H ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Candidaemia; Epidemiology; Mortality; Mycoses; Paediatrics; Risk factors; Treatment

Indexed keywords

ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; CANDIDEMIA; CENTRAL VENOUS CATHETERIZATION; CHILD; CLAVISPORA LUSITANIAE; CLINICAL ARTICLE; COMORBIDITY; CONGENITAL MALFORMATION; FEMALE; HUMAN; INFANT; MALE; MORTALITY; NEOPLASM; OBSERVATIONAL STUDY; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS;

EID: 84856235080     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03720.x     Document Type: Article

References (23)

1. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care 2010; 16: 445-452.
2. Saiman L, Ludington E, Pfaller M et al. Risk factors for candidemia in neonatal intensive care unit patients: the National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19: 319-324.
3. Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003; 22: 686-691.
4. Zaoutis TE, Greves HM, Lautenbach E, Bilker WB, Coffin SE. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J 2004; 23: 635-641.
5. Zaoutis T, Coffin S, Chu J et al. Risk factors for mortality in children with candidemia. Pediatr Infect Dis J 2005; 24: 736-739.
6. Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006; 117: 1680-1687.
7. Neu N, Malik M, Lunding A et al. Epidemiology of candidemia at a Children's hospital, 2002 to 2006. Pediatr Infect Dis J 2009; 28: 806-809.
8. Zaoutis TE, Prasad PA, Localio AR et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010; 51: e38-e45.
9. Dutta A, Palazzi DL. Candida non-albicans versus Candida albicans fungemia in the non-neonatal pediatric population. Pediatr Infect Dis J 2011; 30: 664-668.
10. Roilides E, Kadiltsoglou I, Zahides D, Bibashi E. Invasive candidosis in pediatric patients. Clin Microbiol Infect 1997; 3: 192-197.
11. Roilides E, Farmaki E, Evdoridou J et al. Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis 2004; 23: 745-750.
12. Rodriguez D, Almirante B, Park BJ et al. Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J 2006; 25: 224-229.
13. DIN 58940-84. Medizinische Mikrobiologie - Empfindlichkeitsprüfung von mikrobiellen Krankheitserregern gegen Chemotherapeutika: Mikrodilution - Spezielle Anforderungen an die Testung von Pilzen gegen Antimykotika. Berlin: Normenausschuss Medizin (NAMed) im DIN Deutsches Institut für Normung; e.V., 2002.
14. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard M27-A2. Wayne, PA, USA: Clinical Laboratory Standards Institute, 2002.
15. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis 2011; 69: 45-50.
16. Pappas PG, Rex JH, Lee J et al.; NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-643.
17. Blyth CC, Chen SC, Slavin MA et al.; Australian Candidemia Study. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009;123: 1360-1368.
18. Pasqualotto AC, de Moraes AB, Zanini RR, Severo LC. Analysis of independent risk factors for death among pediatric patients with candidemia and a central venous catheter in place. Infect Control Hosp Epidemiol 2007; 28: 799-804.
19. Zaoutis TE, Foraker E, McGowan KL et al. Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals. Diagn Microbiol Infect Dis 2005; 52: 295-298.
20. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp. Clin Microbiol Infect 2006; 12: 170-177.
21. Festekjian A, Neely M. Incidence and predictors of invasive candidiasis associated with candidaemia in children. Mycoses 2011; 54: 146-153.
22. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-1239.
23. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.